
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.
Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates have typically shown post-infection virological control, but protection against acquisition of infection has previously only been reported against neutralization-sensitive virus challenges. Here we demonstrate vaccine protection against acquisition of fully heterologous, neutralization-resistant simian immunodeficiency virus (SIV) challenges in rhesus monkeys. Adenovirus/poxvirus and adenovirus/adenovirus-vector-based vaccines expressing SIV(SME543) Gag, Pol and Env antigens resulted in an 80% or greater reduction in the per-exposure probability of infection against repetitive, intrarectal SIV(MAC251) challenges in rhesus monkeys. Protection against acquisition of infection showed distinct immunological correlates compared with post-infection virological control and required the inclusion of Env in the vaccine regimen. These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Viral Vaccines
- Simian immunodeficiency virus
- Simian Immunodeficiency Virus
- SAIDS Vaccines
- Neutralization Tests
- Male
- Macaca mulatta
- HIV-1
- General Science & Technology
- Female
Citation

Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Viral Vaccines
- Simian immunodeficiency virus
- Simian Immunodeficiency Virus
- SAIDS Vaccines
- Neutralization Tests
- Male
- Macaca mulatta
- HIV-1
- General Science & Technology
- Female